Faktor-VIII-Konzentrate

K. M. Brinkhous

doi:10.1055/s-0038-1656571

Hämostaseologie, Table of Contents

Hamostaseologie 1982; 02(03): 91-104
DOI: 10.1055/s-0038-1656571

Originalarbeiten

Schattauer GmbH

Faktor-VIII-Konzentrate

Ihre Verwendung bei Hämophilie A und von Willebrandscher Erkrankung

K. M. Brinkhous

¹Universität von North Carolina, Chapel Hill, USA

› Author Affiliations

Abstract

Full Text

References

LITERATUR
1 Brinkhous K. M., Hemker H. C. (Eds.). Handbook of Hemophilia. Part I and II. Excerpta Medica, Amsterdam 1975
2 Menaché D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemo-stasis. Alan R. Liss, New York 1981
3 Zimmerman T. S., Meyer D. Structure and function of factor VIII/von Willebrand factor. In Bloom A. L., Thomas D. P. (Eds.) Haemostasis and Thrombosis. Churchill Livingstone; Edinburgh: 1981: 111-123
4 Kingdon H. S., Hassell T. M. Hemophilic dog model for evaluating hemostatic efficacy of plasma protein fractions. Thromb. Haemost. 1981; 46: 217.
5 Griggs T. R., Potter J., McClanahan S. B., Webster W. P., Brinkhous K. M. Macro-molecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion. Proc. Natl. Acad. Sci. USA 1977; 74: 759-763
6 Thelin G. M., Wagner R. H. Sedimentation of plasma antihemophilic factor. Arch. Biochem. Biophys. 1961; 95: 70-76
7 Owen W. G., Wagner R. H. Antihemophilic factor. A new method of purification. Thromb. Res. 1972; 1: 71-87
8 Vehar G. A., Davie E. W. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980; 19: 401-410
9 Penick G. D., Brinkhous K. M. Relative stability of plasma antihemophilic factor (AHF) under different conditions of storage. Am. J. Med. Sci. 1956; 232: 434-441
10 Sola B., Avner P., Sultan Y., Jeanneau C., Maisonneuve P. Monoclonal antibodies against human factor VIII molecule neutralize antihemophilic factor and ristocetin cofactor activities. Proc. Natl. Acad. Sci. USA 1982; 79: 183-187
11 Seegers W. H., McCoy L. E., Groben H. D., Sakuragawa N., Agrawal B. B. L. Purification and some properties of auto-prothrombin II-A: an anticoagulant perhaps also related to fibrinolysis. Thromb. Res. 1972; 1: 443-460
12 Lamb M. A., Reisner H. M., Cooper H. A., Wagner R. H. The multimeric distribution of factor Vlll-related antigen studied by an improved crossed-immunoelectrophoresis technique. J. Lab. Clin. Med. 1981; 98: 751-763
13 Sarji K. E., Stratton R. D., Wagner R. H., Brinkhous K. M. Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc. Natl. Acad. Sci. USA 1974; 71: 2937-2941
14 Stratton R. D., Wagner R. H., Webster W. P., Brinkhous K. M. Antibody nature of circulating inhibitor of plasma von Willebrand factor. Proc. Natl. Acad. Sci. USA 1975; 72: 4167-4171
15 Furlan M., Perret B. A., Beck E. A. Studies on factor VIII-related protein IV. Interaction of galactose-specific lectins with human factor VIII/von Willebrand factor. Biochim. Biophys. Acta 1980; 623: 402-411
16 Geratz J. D., Tidwell R. R., Brinkhous K. M., Mohammad S. F., Dann O., Loewe H. Specific inhibition of platelet agglutination and aggregation by aromatic amidino compounds. Thromb. Haemost. 1978; 39: 411-425
17 Vukovich T., Koller E., Doleschel W. The influence of thrombin on the platelet-aggregating activity of human factor VIII. A study with insolubilized thrombin. Thromb. Haemost. 1979; 42: 832-837
18 Martin S. E., Marder V. J., Francis C. W., Loftus L. S., Barlow G. H. Enzymatic degradation of the factor-VIII-von-Wille-brand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood 1980; 55: 848-858
19 Switzer M. E., McKee P. A. Studies on human antihemophilic factor: evidence for a covalently linked subunit structure. J. Clin. Invest. 1976; 57: 925-937
20 Triantaphyllopoulos D. C, McGarry B. J. Cryoprecipitates and blood-groups. Lancet 1979; 2: 203.
21 Pepper M. D., Learoyd P. A., Rajah S. M. Plasma factor VIII. variables affecting stability under standard blood bank conditions and correlation with recovery in concentrates. Transfusion 1978; 18: 756-760
22 McLeod B. C., Sassetti R. J., Cole E. R., Pierce M. I. Factor VIII collection by pheresis. Lancet 1980; 2: 671-673
23 Wagner R. H., McLester W. D., Smith M., Brinkhous K. M. Purification of antihemophilic factor (Factor VIII) by amino acid precipitation. Thromb. Diath. Haemorrh. 1964; 11: 64-74
24 Newman J., Johnson A. J., Karpat-kin M. H., Puszkin S. Methods for the production of clinically effective intermediate- and highpurity factor-VIII concentrates. Br. J. Haematol. 1971; 21: 1-20
25 Kang E. P. An improved thaw-siphon method for the cryoprecipitate preparation. Vox Sang. 1980; 38: 172-177
26 Pool J. G., Shannon A. E. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system: assay in vitro and in vivo. N. Engl. J. Med. 1965; 273: 1443-1447
27 Mason E. C. Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII. Lancet 1978; 2: 15-17
28 Toolis F., McKay G., Prowse C. V. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations. Thromb. Haemost. 1980; 43: 25-27
29 Ness P. M., Perkins H. A. Fibrinogen in cryoprecipitate and its relationship to factor VIII (AHF) levels. Transfusion 1980; 20: 93-96
30 Jones P., Martin-Villar J., De Vreker R., Taub R. (Eds.) Management of the hemophilias. Scand. J. Haematol. 1980 24. Suppl.35
31 Aronson D. L. Factor VIII (antihemophilic globulin). Semin. Thromb. Hemost. 1979; 6: 12-27
32 Allain J. P., Verroust F., Soulier J. P. In vitro and in vivo characterization of factor VIII preparations. Vox Sang. 1980; 38: 68-80
33 Blatt P. M., Brinkhous K. M., Gulp H. R., Krauss J. S., Roberts H. R. Antihemophilic factor concentrate therapy in von Wille-brand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. J.A.M. A. 1976; 236: 2770-2772
34 Lee H., Chavin S. I., Blewitt R. E., Austen D. E. G. Large scale purification and characterization of porcine factor VIII for clinical use. Thromb. Haemost. 1977; 38: 349.
35 Johnson A. J., MacDonald V. E., Semar M., Fields J. E., Schuck J., Lewis C., Brind J. Plasma protein fractionation using solid-phase polyelectrolytes. In Curling J. M. (Ed.) Methods of Plasma Protein Fractionation Academic Press; London: 1980: 129-147
36 Costello W. P., Middletown S. M., Malia R. G. A new clinical preparation of high-purity porcine factor VIII :C concentrate. Thromb. Haemost. 1981; 46: 15.
37 Brinkhous K. M. Assay of platelet aggregating von Willebrand factor. In CRC Handbook Series in Clinical Laboratory Science. Section I: Hematology. Vol. III Schmidt R. M. CRC Press; Boca Raton: 1980: 141-147 (Ed.).
38 Langdell R. D., Wagner R. H., Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. J. Lab. Clin. Med. 1953; 41: 637-647
39 Nye S. W., Graham J. B., Brinkhous K. M. The partial thromboplastin time as a screening test for the detection of latent bleeders. Am. J. Med. Sci. 1962; 243: 279-287
40 Brinkhous K. M., Dombrose F. A. Partial thromboplastin time. In CRC Handbook Series in Clinical Laboratory Science. Section I: Hematology. Vol. III Schmidt R. M. CRC Press; Boca Raton: 1980: 221-246 (Ed.).
41 Biggs R., Macfarlane R. G. Human blood coagulation. Thomas, Springfield 1957
42 Biggs R., Douglas A. S. The thromboplastin generation test. J. Clin. Pathol. 6 1953; 23-29
43 Seghatchian M. J., Kemball-Cook G., Barrowcliffe T. W. Absorption of factor VIII by aluminium hydroxide. Haemostasis 1979; 8: 106-116
44 Hoyer L. W. The factor VIII complex: structure and function. In Menache D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemostasis; Alan R. Liss; New York: 1981: 1-26
45 Howard M. A., Firkin B. G. Ristocetin-a new tool in the investigation of platelet aggregation. Thromb. Diath. Haemorrh. 1971; 26: 362-369
46 Read M. S., Shermer R. W., Brinkhous K. M. Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor. Proc. Natl. Acad. Sci. USA 1978; 75: 4514-4518
47 Griggs T. R., Cooper H. A., Webster W. P., Wagner R. H., Brinkhous K. M. Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand factors. Proc. Natl. Acad. Sci. USA 1973; 70: 2814-2818
48 Weiss H. J., Rogers J., Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J. Clin. Invest. 1973; 52: 2697-2707
49 Brinkhous K. M., Read M. S. Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying. frezing, or lyophilization: new stable platelet preparations for von Willebrand factor assays. Thromb. Res. 1978; 13: 591-597
50 Brinkhous K. M., Barnes D. S., Potter J. Y., Read M. S. Von Willebrand syndrome induced by a Bothrops venom factor: bioassay for venom coagglutinin. Proc. Natl. Acad. Sci. USA 1981; 78: 3230-3234
51 Brinkhous K. M., Read M. S. Use of venom coagglutinin and lyophilized platelets in testing for platelet-aggregating von Willebrand factor. Blood 1980; 55: 517-520
52 Miller C. H., Graham J. B., Goldin L. R., Elston R. C. Genetics of classic von Willebrand's disease. I. Phenotypic variation within families. Blood 1979; 54: 117-136
53 Weiss A. E., Webster W. P., Strike L. E., Brinkhous K. M. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid. Transfusion 1976; 16: 209-214
54 Brinkhous K. M., Carney C. N., Shermer R. W. Use of high-potency antihemophilic concentrates in prophylaxis. Thromb. Diath. Haemorrh. Suppl. 1971; 43: 139-147
55 Aronstam A., Wassef M., Choudhury D. P., Turk P. M. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. Lancet 1980; 1: 169-171
56 Brinkhous K. M. Hemophilia. Bull. N. ć. Acad. Med. 1954; 30: 325-342
57 McMillan C. W., Webster W. P., Roberts H. R., Blythe W. B. Continuous intravenous infusion of factor VIII in classic haemophilia. Brit. J. Haematol. 1970; 18: 659-667
58 Aronstam A., McLellan D. S., Turk P. Transfusion requirements of adolescents with severe hemophilia A. J. Clin. Pathol. 32: 927-930 1979;
59 Brinkhous K. M., Swanton M. C., Webster W. P., Roberts H. R. Hemophilic arthropathy: transfusion therapy in its amelioration - canine and human studies. In Van-derfield I. R. (Ed.) Proc. Symp. Hemophilia. Sydney, Australia The Hemophilia Society of N.S.W.; 1966: 18-21
60 Rabiner S. F., Telfer M. C. Home transfusion for patients with hemophilia A. N. Engl. J. Med. 1970; 283: 1011-1015
61 Franklin F. I. Trends in the treatment of hemophilia A: patient-administered clotting factor program. Thromb. Diath. Haemorrh. Suppl. 1971; 43: 467-470
62 Levine P. H., Britten A. F. H. Supervised patient-management of hemophilia. Ann. Intern. Med. 1973; 78: 195-201
63 Kasper C. K. Self-infusion treatment program. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 597-603
64 Rabiner S. F. Home infusion treatment program. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 591-596
65 Van Eys J. Home transfusion for hemophilia. In Hilgartner M. W. (Ed.) Hemophilia in Children Publishing Sciences Group; Littleton (Mass.): 1976: 185-200
66 Evensen S. A., Thaule R., Groan K. Self-therapy for haemophilia in Norway. Acta Med. Scand. 1979; 205: 395-399
67 Deutsch E. Die Hemmkörperhämophilie. Springer, Wien 1950
68 Brinkhous K. M., Shanbrom E., Roberts H. R., Webster W. P., Fekete L., Wagner R. H. A new high-potency glycine-pre-cipitated antihemophilic factor (AHF) concentrate. J.A.M.A. 1968; 205: 613-617
69 Allain J. P., Roberts H. R. Treatment of acute bleeding episodes in hemophilic patients with specific factor VIII antibodies. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 659-671
70 Lechner K. Report of the Working Party on Acquired Inhibitors to Coagulation Fac tors. 26th Annual Meeting, International Committee on Thrombosis and Haemos-tasis, Boston 1980
71 Roberts H. R., Knowles M. R., Jones T. L., McMillan C. W. Use of factor VIII concen trates in the management of patients with factor VIII inhibitors. In Brinkhous K. M. (Ed.) Hemophilia and New Hemorrhagic States University of North Carolina Press; Chapel Hill: 1970: 152-163
72 Blatt P. M., White G. C., McMillan C. W., Roberts H. R. Treatment of anti-factor VIII antibodies. Thromb. Haemost. 1977; 38: 514-523
73 Biggs R. (ed.) The Treatment of Haemophilia A and B and von Willebrand's Disease. Blackwell; Oxford: 1978
74 Brackmann H. H., Etzel R., Hofmann P., Egli H. The successful treatment of acquired inhibitors against factor VIII. Thromb. Haemost. 1977; 38: 369.
75 Bennett E., Dormandy K. Pool's cryo-precipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-IX deficiency. Lancet 1966; 2: 731-732
76 Sultan Y. Rationale for the treatment of von Willebrand's disease. In Menache D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemostasis. Alan R. Liss; New York: 1981
77 Brinkhous K. M., Culp H. R. Quantitation of von Willebrand factor and an antibody inhibitor. Thromb. Res. 8, Suppl. II: 1976; 125-132
78 Bloom A. L., Peake I. R., Furlong R. A., Davies B. L. High potency factor VIII concentrate: more effective than cryoprecipi-tate in a patient with von Willebrand's disease and inhibitor. Thromb. Res. 1979; 16: 847-852
79 Ness P. M., Perkins H. A. Cryoprecipitate as a reliable source of fibrinogen replacement. J.A.M.A. 1979; 241: 1690-1691
80 Snyder E. L., Mosher D. F., Hezzey A., Golenkowsky G. Effect of blood transfusion on in vivo levels of plasma fibronectin. J. Lab. Clin. Med. 1981; 98: 336-341
81 Fratantoni J. C., Aronson D. L. (Eds.). Unsolved Therapeutic Problems in Hemophilia. DHEW Publication No. (NIH) 1977; 77-1089
82 Brinkhous K. M., Roberts H. R., Weiss A. E. Prevalence of inhibitors in hemophilia A and B. Thromb. Diath. Haemorrh. Suppl. 1972; 51: 315-320
83 Shapiro S. S., Hultin M. Acquired inhibitors to the blood coagulation factors. Sem. Thromb. Hemost. 1975; 1: 336-385
84 Sultan Y., Maisonneuve P. Incidence des inhibiteurs du facteur VIII dans la population des hemophiles francais. Nouv. Rev. fr. Hemat. 1977; 18: 671-673
85 Frommel D., Allain J. P., Saint-Paul E., Bosser C., Noël B., Mannucci P. M., Pan-nicucci F., Blombäck M., Prou-Wartelle O., Muller J. Y. HLA antigens and factor VIII antibody in classic hemophilia. Thromb. Haemost. 1981; 46: 687-689
86 Bloom A. L. Current status and trends in the treatment of hemophilic patients with inhibitors. In Menache D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemostasis Alan R. Liss; New York: 1981: 123-138
87 Vermylen J. Complications of infusion therapy - reaction to infusion. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 605-611
88 Rosati L. A., Barnes B., Oberman H. A., Penner J. A. Hemolytic anemia due to anti-A in concentrated antihemophilic factor preparations. Transfusion 1970; 10: 139-141
89 Orringer E. P., Koury M. J., Blatt P. M., Roberts H. R. Hemolysis caused by factor VIII concentrates. Arch. Intern. Med. 1976; 136: 1018-1020
90 Shapiro S. Antibody responses in the hemophiliac. In Fratantoni J. C, Aronson D. L. (Eds.) Unsolved Problems in Hemophilia 103-111. DHEW Publication No.; (NIH): 1977: 77-1089
91 Prager D., Djerassi I., Eyster M. E., Gill F. M., Kajani N. K., Lewis J. H., Lusch S., Shapiro S. S. Pennsylvania state-wide hemophilia program: summary of immediate reactions with the use of factor VIII and factor IX concentrate. Blood 1979; 53: 1012-1013
92 Eyster M. E., Nau M. E. Particulate material in antihemophilic factor (AHF) concentrates. Transfusion 1978; 18: 576-581
93 Boese E. C, Tantum K. R., Eyster M. E. Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates. Am. J. Med. 1979; 67: 474-476
94 Grignani G., Gamba G., Ascani E. »In vivo« platelet aggregates after replacement therapy in patients with hemophilia A. Thromb. Haemost. 1979; 42: 813-814
95 Holmberg L., Ljung R. Purification of F. VIII:C by antigen-antibody chromatography. Thromb. Res. 1978; 12: 667-675
96 Baxter Travenol signs pact for biotechnology work on clotting agent. Wall Street Journal, April 2. 1982